JP Morgan Chase
VOR icon

JP Morgan Chase’s Vor Biopharma VOR Stock Holding History

JP Morgan Chase’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$402K Buy
21,621
+17,257
+395% +$261K ﹤0.01% 5234
2026
Q1 		$64.2K Buy
4,364
+2,052
+89% +$28.9K ﹤0.01% 6074
2025
Q4 		$30.2K Buy
2,312
+2,234
+2,864% +$41.6K ﹤0.01% 6409
2025
Q3 		$3.8K Sell
78
-372
-83% -$15K ﹤0.01% 6814
2025
Q2 		$14.6K Buy
450
+357
+384% +$3.15K ﹤0.01% 6248
2025
Q1 		$1.33K Sell
93
-440
-83% -$10.6K ﹤0.01% 6594
2024
Q4 		$11.8K Sell
533
-69
-11% -$1.14K ﹤0.01% 6358
2024
Q3 		$8.43K Buy
602
+553
+1,129% +$10.1K ﹤0.01% 6399
2024
Q2 		$983 Sell
49
-760
-94% -$24.6K ﹤0.01% 6623
2024
Q1 		$38.4K Sell
809
-416
-34% -$18.3K ﹤0.01% 6031
2023
Q4 		$55.1K Sell
1,225
-40
-3% -$1.65K ﹤0.01% 5965
2023
Q3 		$53.7K Sell
1,265
-281
-18% -$15.2K ﹤0.01% 5781
2023
Q2 		$95.5K Sell
1,546
-4,851
-76% -$443K ﹤0.01% 5480
2023
Q1 		$689K Hold
6,397
– – ﹤0.01% 4297
2022
Q4 		$851K Sell
6,397
-57
-0.9% -$5.64K ﹤0.01% 4162
2022
Q3 		$514K Sell
6,454
-2,115
-25% -$208K ﹤0.01% 4448
2022
Q2 		$852K Sell
8,569
-590
-6% -$60.4K ﹤0.01% 4221
2022
Q1 		$1.11M Sell
9,159
-1,039
-10% -$177K ﹤0.01% 4189
2021
Q4 		$2.37M Sell
10,198
-1,193
-10% -$344K ﹤0.01% 3723
2021
Q3 		$3.57M Buy
11,391
+10,860
+2,045% +$3.23M ﹤0.01% 3320
2021
Q2 		$199K Sell
531
-1,083
-67% -$534K ﹤0.01% 5252
2021
Q1 		$1.39M Buy
+1,614
New +$1.37M ﹤0.01% 3977

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

JP Morgan Chase's VOR Position: Q2 2026 in Review

JP Morgan Chase increased its Vor Biopharma (VOR) stake by 395% in Q2 2026, buying an estimated $261K and bringing the position to 21,621 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #5234.

JP Morgan Chase first reported a position in VOR in Q1 2021 and has held it in 22 quarters since. The position peaked at $3.57M in Q3 2021. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • JP Morgan Chase held 21,621 shares of Vor Biopharma worth $402K as of Q2 2026.
  • JP Morgan Chase bought 17,257 Vor Biopharma shares in Q2 2026, an estimated $261K.
  • Vor Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5234 holding.
  • JP Morgan Chase first reported a position in Vor Biopharma in Q1 2021 and has held it in 22 quarters since.
  • JP Morgan Chase's Vor Biopharma position peaked at $3.57M in Q3 2021.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.